Quest Diagnostics has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma for $485 million in cash, as part of pharma deals. Read the full story
Quest Diagnostics has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma for $485 million in cash, as part of pharma deals. Read the full story
The Lymphoma Partnering 2007-2012 provides understanding and access to the lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies Read the full story